PhD research fellowship: Pharmacometrics & Computational Disease Modelling

 

The Graduate Research Training Program PharMetrX: Pharmacometrics &
Computational Disease Modelling is an interdisciplinary PhD program bridging
pharmacy and mathematics. PharMetrX provides its graduate students a unique
opportunity to experience research in drug development and optimising drug
therapy.

 

PharMetrX offers: 

- a transdisciplinary research environment and research program

- a competitive 3.5 years research fellowship

- a structured research training curriculum of specifically designed
academic and industrial modules

- a joint supervision of the scientific progress by both program chairs

- an individual research and development plan

- an individual mentorship from one of the industry partners

 

We are currently inviting applications to start the PharMetrX PhD program in
March 2017. 

PharMetrX PharMetrX is open to candidates with a university degree in
pharmacy, mathematics/statistics, natural sciences or medicine. 

 

Deadline for applications:  September 15th, 2016. 

For details see  <https://www.PharMetrX.de> https://www.PharMetrX.de.

 

PharMetrX is a joint program of the Freie Universität Berlin and the
Universität Potsdam, supported by several global research-driven
pharmaceutical companies.

 

Charlotte Kloft & Wilhelm Huisinga

Program Chairs

 

 

---------------------------------------------------------------------

Cornelia Böhnstedt

Program Coordinator


Graduate Research Training Program PharMetrX:

Pharmacometrics & Computational Disease Modelling

at the Freie Universität Berlin and the Universität Potsdam

 

E-mail:  <mailto:cornelia.boehnst...@fu-berlin.de>
cornelia.boehnst...@fu-berlin.de

Phone: +49 (030) 838-51726

Office hours: Mon 08:00 – 15:30 / Tue 08:00 – 15:30 / Thu 08:00 – 15:30

- In between flexible working hours - 

 

 <http://www.clinical-pharmacy.eu/> www.clinical-pharmacy.eu

 <http://www.pharmetrx.de/> www.PharMetrX.de 

--------------------------------------------------------------------

 

Reply via email to